Technology | Clinical Decision Support | April 30, 2018

Point of Care Decision Support Releases New Version of Anticoagulation Software

Clinical decision support software version 2.0 adds new features, improves performance and supports CMS reimbursement requirements

Point of Care Decision Support Releases New Version of Anticoagulation Software

Image courtesy of Point of Care Decision Support

April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their anticoagulation clinical decision support (CDS) software. The application was developed with leading clinical thrombosis experts to specifically address the new and complex challenges of managing both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs). It enables healthcare provider teams to deliver consistent, measurable and evidence-based quality of care for patients on anticoagulants.

Key benefits to healthcare practitioners that electronically document care for patients on an oral anticoagulant therapy include:

  • Central patient dashboard that allows them to understand the patient's history and plan in less than 60 seconds;
  • Automatic dosage calculations using validated nomograms to assist in medication management;
  • Integration with validated survey instruments such as CHA2DS2-VASc, HAS-BLED and HEMORR2HAGES;
  • Full patient plan of care instructions available to print, providing a customized and relevant shared patient/clinician experience;
  • Electronic medical record (EMR)-agnostic integration with bidirectional flow of patient data that dramatically decreases data entry; and
  • Enhanced reporting options that meet Centers for Medicare and Medicaid Services (CMS)/Medicare Access and CHIP Reauthorization Act (MACRA) "high activity" improvement requirements.

PCDS demonstrated AC 2.0 at the AC Forum Boot Camp for physicians, nurses and pharmacists that work with patients on oral anticoagulant therapies, April 23-24 in Austin, Texas.

For more information: www.ptofcare.com

 

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init